Early research in older adults found an experimental vaccine prevented nearly two-thirds of serious cases of a common, seasonal respiratory virus that annually kills thousands of vulnerable people - babies and senior citizens. If further testing by vaccine developer Novavax Inc. goes well, in a few years the biotech company's genetically engineered shot could become the first vaccine approved against respiratory syncytial virus, or RSV.